Cardiac hypertrophy induced by PPAR-γ agonist treatment occurs independently of changes in myocardial insulin signaling

被引：0
|
作者：
Rasmussen, I
McQueen, AP
Zaha, VG
Litwin, SE
Berger, JP
Abel, ED
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] Merck & Co Inc, Rahway, NJ 07065 USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1541
引用
收藏
页码：321 / 322
页数：2
相关论文
共 50 条
  • [31] Moderate exercise mitigates cardiac dysfunction and injury induced by cyclosporine A through activation of the PGI2 / PPAR-γ signaling pathway
    Nourmohammadi, Khatereh
    Bayrami, Abolfazl
    Naderi, Roya
    Shirpoor, Alireza
    Soraya, Hamid
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2023, 18 (06) : 696 - 707
  • [32] SEVERITY OF CARDIAC-HYPERTROPHY GRADES THE EXTENT OF CHANGES INDUCED IN THE MYOCARDIAL ACTION-POTENTIAL
    ROBERTSON, L
    BASSETT, A
    TENEICK, R
    FEDERATION PROCEEDINGS, 1983, 42 (04) : 1113 - 1113
  • [33] PPAR delta inhibits angiotensin II induced cardiac hypertrophy by suppressing intracellular Ca2+ signaling pathway
    Lee, K. S.
    Park, J. H.
    Lee, S. H.
    Go, S. H.
    Lim, H. J.
    Choi, H. E.
    Park, H. Y.
    EUROPEAN HEART JOURNAL, 2007, 28 : 367 - 367
  • [34] Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure
    Korstjens, IJM
    Rouws, CHFC
    Van der Laarse, WJ
    Van der Zee, L
    Stienen, GJM
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2002, 23 (01) : 93 - 102
  • [35] Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure
    I.J.M. Korstjens
    C.H.F.C. Rouws
    W.J. Van Der Laarse
    L. Van Der Zee
    G.J.M. Stienen
    Journal of Muscle Research & Cell Motility, 2002, 23 : 93 - 102
  • [36] HIV protease Inhibitor(PI) therapy-induced hypertriglyceridemia occurs independently of insulin resistance, diabetes and changes in body weight
    Carpentier, A
    Leung, N
    Walmsley, S
    Salit, I
    Lewis, GF
    DIABETES, 2001, 50 : A450 - A451
  • [37] Muscle ring finger-1 (MuRF1) inhibits spontaneous cardiac hypertrophy induced by the PPARα agonist fenofibrate in vivo
    Willis, Monte S.
    Li, Luge
    Schisler, Jonathan C.
    Lockyer, Pamela
    Patterson, Cam
    FASEB JOURNAL, 2010, 24
  • [38] ET-1-induced cardiac hypertrophy is inhibited by activation of PPAR-α via blockade of Jun NH2-terminal kinase pathway.
    Takanashi, M
    Miyauchi, T
    Irukayama, Y
    Sakai, S
    Kasuya, Y
    Ogata, T
    Iemitsu, M
    Sudo, T
    Goto, K
    Yamaguchi, I
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 91 : 104P - 104P
  • [39] Insulin-Like Growth Factor I Receptor Signaling Is Required for Exercise-Induced Cardiac Hypertrophy
    Kim, Jaetaek
    Wende, Adam R.
    Sena, Sandra
    Theobald, Heather A.
    Soto, Jamie
    Sloan, Crystal
    Wayment, Benjamin E.
    Litwin, Sheldon E.
    Holzenberger, Martin
    LeRoith, Derek
    Abel, E. Dale
    MOLECULAR ENDOCRINOLOGY, 2008, 22 (11) : 2531 - 2543
  • [40] A dual PI3K-mTOR inhibitor induced cardiac hypertrophy in mice: Role of the insulin signaling
    Onufrak, Jillian
    Yang, Yongayo
    Lee, Juyong
    Fuseler, John
    Sun, Maoyun
    Sasi, Sharath
    McDonald, J. Tyson
    Hlatky, Lynn
    Price, Robert L.
    Carrozza, Joseph
    Goukassian, David
    Borg, Thomas K.
    Morgan, James P.
    Yan, Xinhua
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
12345